Uclés VV, Rodríguez CG

Idioma: Español
Referencias bibliográficas: 24
Paginas: 1-10
Archivo PDF: 273.17 Kb.

RESUMEN

Los efectos secundarios de medicamentos quimioterapéuticos han sido analizados como métodos de posible afectación neurológica además la sobrevida de los pacientes expuestos a los tratamientos los han puesto en evidencia, aumentando años de vida y con lo anterior se logra analizar el posible deterioro cognitivo. El siguiente articulo pretende dar una idea más clara de algunas de las investigaciones con respecto al daño neurológico que algunos paciente con quimioterapéuticos podrían presentar, y si esto se podría deber al propio tratamiento o como una manifestación más de la enfermedad de fondo, como podría ser una posible metástasis a sistema nervioso central. La idea fundamental es plantear los puntos a tomar en cuenta y características en las que los clínicos o médicos tratantes deben enfocarse para un abordaje integral de del paciente.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Mitchell T, Turton P. Chemobrain’: concentration and memory effects in people receiving chemotherapy – a descriptive phenomenological study. England (2011) european journal of cancer care 20, 539–548.

2. Jamie S. Myers, Chemotherapy-related cognitive impairment: neuroimaging, neuropsychological testing, and the neuropsychologist. Clinical journal of oncology nursing. volume 13, number 4, pag 413-421.

3. Arash Asher, Cognitive dysfunction among cancer survivors. American journal of physical medicine & rehabilitation. Am. J. Phys. Med. Rehabil. & vol. 90, no. 5 (suppl), may 2011. S16-s26

4. Arti Hurria, George Somlo, Tim Ahles, Renaming “Chemobrain”. Informa Healthcare USA, Cancer Investigation, 25:373–377, 2007

5. Anthony S. Fauci et al, Harrison, Principios de medicina interna. Edición 17. Mc Graw Hill. México 2009. 479-747.

6. Adva Avisar, Yaron River, Elad Schiff, et al, Chemotherapy-related cognitive impairment: does integrating complementary medicine have something to add? 2011. Review of the Literature. Breast cancer res treat (2012) 136:1–7.

7. Yu Dong, Catherine Crone, Thomas Wise. Chemobrain. Psychiatric annals. vol. 44, no. 7, 2014. 334-338.

8. Catherine E. Jansen, Christine A. Miaskowski, Faan, et al. A meta-analysis of the sensitivity of various neuropsychological tests used to detect chemotherapy-induced cognitive impairment in patients with breast cancer. Oncology nursing forum - vol 34, no 5, 2007. 997-1005.

9. Je Fardell, J Vardy, In Johnston, et al, Chemotherapy and cognitive impairment: treatment options.clinical pharmacology & therapautics. 2011, 365-376.

10. Varsha Dutta, Chemotherapy, Neurotoxicity, and Cognitive changes in breast cancer. journal of cancer research and therapeutics - july-september 2011 - volume 7 - issue 3, pag 264-269.

11. Sonia López-Santiago, Juan A. Cruzado y Jaime Feliú. Chemobrain: revisión de estudios que evalúan el deterioro cognitivo de supervivientes de cáncer tratados con quimioterapia. España. Psicooncología. Vol. 8, núm. 2-3, 2011, pp. 265-280.

12. K. Hermelink et al. Two different sides of ‘Chemobrain’: determinants and nondeterminants of self-perceived cognitive dysfunction in a prospective, randomized, multicenter study germany. (2010) Psycho-oncology 19: 1321–1328.

13. Miyuki Ono, James M. Ogilvie, Jennifer S. Wilson, et al. A meta-analysis of cognitive impairment and decline associated with adjuvant chemotherapy in women with breast cancer. Revista frontiers in oncology, 2015, artículo 59: 1-19.

14. Jeffrey S. Wefel, Shelli R. Kesler, Kyle R. Noll, et al. Clinical Characteristics, Pathophysiology, and Management of noncentral nervous system, Cancer-related cognitive impairment in adults, sponsored by the american cancer society, 2015. Volume 65 number 2. 123-138.

15. Caroline H. Walker, Barbara A. Drew, James W. et al. Neurocognitive effects of chemotherapy and endocrine therapies in the Treatment of breast cancer: recent perspectives. 2012 informa healthcare USA, Cancer Investigation, 30:135–148.

16. Lori-Ann Christie, Munjal M. Acharya, Vipan K. Parihar, et al. Impaired Cognitive Function and Hippocampal Neurogenesis following Cancer Chemotherapy 18(7) April 1, 2012. USA American Association for Cancer Research. 1954-1966.

17. Yin Ting Cheung, Si Rong Lim, Han Kiat Ho, et al. Cytokines as mediators of chemotherapy- associated cognitive changes: current evidence, limitations and directions for future research. Singapore 2013. Plos one, volumen 8: 1-12.

18. Sophie Taillibert, Dorothe´e Voillery and Chantal Bernard-Marty. Chemobrain: is systemic chemotherapy neurotoxic? Current Opinion in Oncology 2007, 19:623–627.

19. Pascal Jean-Pierre & Douglas Johnson- Greene. Neuropsychological care and rehabilitation of cancer patients with chemobrain: strategies for evaluation and intervention development Support Care Cancer (2014) 22:2251–2260.

20. Marta Simó, Xavier Rifà-Ros, Antoni Rodriguez-Fornell, et al. A systematic review of structural and functional neuroimaging studies. Neuroscience and Biobehavioral. 2013. Reviews 37 1311–1321.

21. Beatriz Rubio, Agustina Sirgo, Eva Forcadell, et al, cognitive impairment induced by systemic oncological treatments in nonetastatic breast cancer: a review. Psicooncologia. . Vol. 6, Núm. 1, 2009, pp. 83-120.

22. Panoz-Brown, D., Carey, L.M., Smith, A.E, et al. The chemotherapeutic agent paclitaxel selectively impairs reversal learning while sparing prior learning, new learning and episodic memory, Neurobiology of Learning and Memory (2017).

23. David MacKintosh et al, Olanzapine induced delirium—a “probable” adverse drug reaction. 1Palliative Medicine, Central Coast Palliative Care Service, Killarney Vale, NSW, Australia; 2School of Medicine and Public Health, University of Newcastle, Newcastle, Australia. 2017.

24. Jennifer R. Klemp, Jamie S. Myers, Carol J. Fabian, et al. Cognitive functioning and quality of life following chemotherapy in pre- and peri-menopausal women with breast cancer. Support Care Cancer. 2017.